Loading
companiesCompany
POINT Biopharma
POINT Biopharma developed radioactive medicines that home in on prostate cancer and neuroendocrine tumours, and built a large manufacturing campus in Indianapolis. Eli Lilly bought the company at the end of 2023.
Overview
POINT Biopharma Global Inc. (formerly Nasdaq: PNT) was an Indianapolis radiopharmaceutical company with late-stage radioligand therapies: PNT2002, a PSMA-targeted therapy for metastatic castration-resistant prostate cancer after progression on hormonal treatment, and PNT2003, a somatostatin receptor (SSTR)-targeted therapy for gastroenteropancreatic neuroendocrine tumours, both partnered with Lantheus outside certain Asian territories, plus earlier clinical and preclinical programmes. It operated a 180,000 square foot radiopharmaceutical manufacturing campus in Indianapolis and an R&D centre in Toronto. On 2 October 2023 Eli Lilly agreed to acquire POINT through a cash tender offer of USD 12.50 per share, and the merger was completed in late December 2023; the company website now redirects to lilly.com.
Headquarters
Indianapolis, IN, US
Funding
All startupsAcquiredAcquired by Eli Lilly (incl. Loxo)
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Acquisition · Cash tender offer at USD 12.50 per share, an aggregate of approximately USD 1.4 billion, under a merger agreement dated 2 October 2023; completion reported in an 8-K filed 27 December 2023 | 2023 | $1.4B | sec.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Stage
Acquired
Website
Notes
top- pointbiopharma.com redirects to lilly.com, recorded as the website. Deal value and pipeline details come from the Lilly press release filed as exhibit 99.4 to POINT's 8-K of 3 October 2023.
Similar pages
- TechnologyRadioligand plus DNA-repair inhibitor combinations
Shares Somatostatin receptor 2, PSMA, Radioligand therapy (beta emitters), Neuroendocrine tumours.
- TrialA Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
Shares PSMA, Prostate cancer.
- CompanyARTBIO
Shares PSMA, Radioligand therapy (beta emitters), Prostate cancer.
- PersonJeremie Calais
Shares PSMA, Radioligand therapy (beta emitters), Prostate cancer.
- TrialA Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC
Shares PSMA, Prostate cancer.
- PersonSimron Singh
Shares Somatostatin receptor 2, Radioligand therapy (beta emitters), Neuroendocrine tumours.
- PersonPeter Bartenstein
Shares PSMA, Radioligand therapy (beta emitters), Prostate cancer.
- PersonJohannes Czernin
Shares PSMA, Radioligand therapy (beta emitters), Prostate cancer.